Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.
Pharmacotherapy
; 21(2): 142-8, 2001 Feb.
Article
en En
| MEDLINE
| ID: mdl-11213849
ABSTRACT
STUDY OBJECTIVE:
To evaluate epidemiology, resistance, and treatment outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam for 72 hours or longer.DESIGN:
Retrospective analysis.SETTING:
University teaching hospital. PATIENTS Forty-eight patients with A. baumannii bacteremia. INTERVENTION Evaluation of susceptibility and clinical data from 48 patients treated with either ampicillin-sulbactam or imipenem-cilastatin from 1987-1999. MEASUREMENTS AND MAINRESULTS:
Comparing ampicillin-sulbactam and imipenem-cilastatin, there were no differences between days of bacteremia (4 vs 2 days, p=0.05), days to resolution of temperature or white blood cell count, success or failure during or at end of treatment, or intensive care unit total or antibiotic-related length of stay (13 vs 10 days, p=0.05). Patients treated with ampicillin-sulbactam had significantly decreased antibiotic treatment costs (1500 dollars vs 500 dollars, p=0.004).CONCLUSION:
Ampicillin-sulbactam is at least as effective as imipenem-cilastatin based on clinical response at days 2, 7, and end of treatment and is a cost-effective alternative for treatment of A. baumannii infections.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por Acinetobacter
/
Cilastatina
/
Sulbactam
/
Imipenem
/
Bacteriemia
/
Quimioterapia Combinada
/
Ampicilina
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pharmacotherapy
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos